Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John Rotrosen

Showing results (91-100 of 157) with videos related to

Pageof 16
Sort By:
Journal of Substance Use and Addiction Treatment|December 9, 2025
A clinical trial loses access to some of its experimental treatment conditions: What can be done?Sarah Meyers-Ohki, Matisyahu Shulman, Roger D Weiss, et al.
Drug and Alcohol Dependence|September 8, 2022
Buprenorphine & methadone dosing strategies to reduce risk of relapse in the treatment of opioid use disorderKara E Rudolph, Nicholas T Williams, Alicia T Singham Goodwin, et al.
The American Journal of Drug and Alcohol Abuse|August 28, 2020
Variants of opioid genes and response to treatment of opioid use disorder with buprenorphine-naloxone versus extended-release naltrexone in CaucasiansMatthew Randesi, John Rotrosen, Edward V Nunes, et al.
Journal of Addiction Medicine|May 22, 2024
Machine Learning-Driven Analysis of Individualized Treatment Effects Comparing Buprenorphine and Naltrexone in Opioid Use Disorder Relapse PreventionMajid Afshar, Emma J Graham Linck, Alexandra B Spicer, et al.
Trials|January 19, 2024
Optimizing the use of ketamine to reduce chronic postsurgical pain in women undergoing mastectomy for oncologic indication: study protocol for the KALPAS multicenter randomized controlled trialJing Wang, Lisa V Doan, Deborah Axelrod, et al.
Contemporary Clinical Trials|October 1, 2016
Ethical and clinical safety considerations in the design of an effectiveness trial: A comparison of buprenorphine versus naltrexone treatment for opioid dependenceEdward V Nunes, Joshua D Lee, Dominic Sisti, et al.
Drug and Alcohol Dependence|December 22, 2020
An alternative analysis of illicit opioid use during treatment in a randomized trial of extended-release naltrexone versus buprenorphine-naloxone: A per-protocol and completers analysisMary M Mitchell, Robert P Schwartz, Tse-Hwei Choo, et al.
Contemporary Clinical Trials|November 4, 2022
Psilocybin for alcohol use disorder: Rationale and design considerations for a randomized controlled trialKelley C O'Donnell, Sarah E Mennenga, Lindsey T Owens, et al.
The American Journal of Managed Care|November 20, 2018
Cost of pharmacotherapy for opioid use disorders following inpatient detoxificationKathryn E McCollister, Jared A Leff, Xuan Yang, et al.
Journal of Addiction Medicine|October 3, 2023
Secondary Analysis of Agreement Between Negative Timeline Follow Back Report and Negative Urine Toxicology in a Large Trial of Individuals with Opioid Use DisorderMatisyahu Shulman, Tse-Hwei Choo, Jennifer Scodes, et al.
Pageof 16

Showing results (91-100 of 157) with videos related to

Sort By:
Pageof 16
Journal of Substance Use and Addiction Treatment|December 9, 2025
A clinical trial loses access to some of its experimental treatment conditions: What can be done?Sarah Meyers-Ohki, Matisyahu Shulman, Roger D Weiss, et al.
Drug and Alcohol Dependence|September 8, 2022
Buprenorphine & methadone dosing strategies to reduce risk of relapse in the treatment of opioid use disorderKara E Rudolph, Nicholas T Williams, Alicia T Singham Goodwin, et al.
The American Journal of Drug and Alcohol Abuse|August 28, 2020
Variants of opioid genes and response to treatment of opioid use disorder with buprenorphine-naloxone versus extended-release naltrexone in CaucasiansMatthew Randesi, John Rotrosen, Edward V Nunes, et al.
Journal of Addiction Medicine|May 22, 2024
Machine Learning-Driven Analysis of Individualized Treatment Effects Comparing Buprenorphine and Naltrexone in Opioid Use Disorder Relapse PreventionMajid Afshar, Emma J Graham Linck, Alexandra B Spicer, et al.
Trials|January 19, 2024
Optimizing the use of ketamine to reduce chronic postsurgical pain in women undergoing mastectomy for oncologic indication: study protocol for the KALPAS multicenter randomized controlled trialJing Wang, Lisa V Doan, Deborah Axelrod, et al.
Contemporary Clinical Trials|October 1, 2016
Ethical and clinical safety considerations in the design of an effectiveness trial: A comparison of buprenorphine versus naltrexone treatment for opioid dependenceEdward V Nunes, Joshua D Lee, Dominic Sisti, et al.
Drug and Alcohol Dependence|December 22, 2020
An alternative analysis of illicit opioid use during treatment in a randomized trial of extended-release naltrexone versus buprenorphine-naloxone: A per-protocol and completers analysisMary M Mitchell, Robert P Schwartz, Tse-Hwei Choo, et al.
Contemporary Clinical Trials|November 4, 2022
Psilocybin for alcohol use disorder: Rationale and design considerations for a randomized controlled trialKelley C O'Donnell, Sarah E Mennenga, Lindsey T Owens, et al.
The American Journal of Managed Care|November 20, 2018
Cost of pharmacotherapy for opioid use disorders following inpatient detoxificationKathryn E McCollister, Jared A Leff, Xuan Yang, et al.
Journal of Addiction Medicine|October 3, 2023
Secondary Analysis of Agreement Between Negative Timeline Follow Back Report and Negative Urine Toxicology in a Large Trial of Individuals with Opioid Use DisorderMatisyahu Shulman, Tse-Hwei Choo, Jennifer Scodes, et al.
Pageof 16